Sorafenib

Generic Name
Sorafenib
Brand Names
Nexavar, Sorafenib Accord
Drug Type
Small Molecule
Chemical Formula
C21H16ClF3N4O3
CAS Number
284461-73-0
Unique Ingredient Identifier
9ZOQ3TZI87
Background

Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...

Indication

Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

Associated Conditions
Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Associated Therapies
-
Clinical Trials
Related News

Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer

First Posted Date
2019-11-14
Last Posted Date
2019-11-14
Lead Sponsor
Guangxi Medical University
Target Recruit Count
50
Registration Number
NCT04163237
Locations
🇨🇳

TaoBai, Nanning, Guangxi, China

Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma

First Posted Date
2019-11-05
Last Posted Date
2019-11-05
Lead Sponsor
Guangxi Medical University
Target Recruit Count
50
Registration Number
NCT04152356
Locations
🇨🇳

TaoBai, Nanning, Guangxi, China

Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC

First Posted Date
2019-10-29
Last Posted Date
2020-03-25
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
158
Registration Number
NCT04143191
Locations
🇨🇳

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

First Posted Date
2019-10-23
Last Posted Date
2023-08-15
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
60
Registration Number
NCT04135690
Locations
🇨🇳

Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

First Posted Date
2019-10-15
Last Posted Date
2021-07-23
Lead Sponsor
Beijing Ditan Hospital
Target Recruit Count
72
Registration Number
NCT04127396
Locations
🇨🇳

Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China

Sorafenib PK in Patients With Advanced HCC and Child-Pugh B

First Posted Date
2019-08-09
Last Posted Date
2019-08-21
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
5
Registration Number
NCT04051853
Locations
🇳🇱

Academic Medical Center, Amsterdam, Netherlands

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

First Posted Date
2019-07-31
Last Posted Date
2024-05-02
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
732
Registration Number
NCT04039607
Locations
🇺🇸

Local Institution - 0295, Newark, New Jersey, United States

🇧🇷

Local Institution - 0061, Salvador, Bahia, Brazil

🇦🇺

Local Institution - 0038, Liverpool, New South Wales, Australia

and more 202 locations

A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion

First Posted Date
2019-06-03
Last Posted Date
2021-04-14
Lead Sponsor
White Plains Hospital
Target Recruit Count
200
Registration Number
NCT03971201
Locations
🇨🇳

Eastern Hepatobiliary Surgery Hospital, Shanghai, China

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

First Posted Date
2019-04-02
Last Posted Date
2024-02-28
Lead Sponsor
Humanity & Health Medical Group Limited
Target Recruit Count
30
Registration Number
NCT03899428
Locations
🇭🇰

Humanity & Health Research Centre, Hong Kong, Hong Kong SAR, Hong Kong

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy